BioSpace News Archive

Drug Development

Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced the dosing of the first patient in the Phase 2 CIRRUS-HCM trial of EDG-7500.

May 6, 2024
·
8 min read
FDA

Phonak Announces FDA Cleared Self-Replacement Option for Lyric™ Hearing Device

Phonak today announces an FDA cleared self-replacement option for Phonak Lyric, the world’s only 100% invisible hearing aid that provides 24/7 hassle-free hearing with proven tinnitus relief.

May 6, 2024
·
3 min read
Lone Star Bio

Chrysalis BioTherapeutics Selected to Present at Respiratory Innovation Summit

Chrysalis BioTherapeutics today announced it was selected to participate in the 2024 Respiratory Innovation Summit (RIS) at the American Thoracic Society Meeting in San Diego.

May 6, 2024
·
2 min read
Biotech Bay

Sampling Human Ships its First Kits for Cellular Analysis to Early Access Customers and Releases an App Note with BMG LABTECH

Sampling Human, Inc., a techbio company developing single cell technologies, announces the delivery of its Apoptosis Biocytometry Kits to Early Access customers.

May 6, 2024
·
3 min read
Biotech Beach

Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant

Webinar, moderated by Cantor Fitzgerald, will be held on Monday, May 13, 2024, at 2:00 p.m. ET.

May 6, 2024
·
3 min read
Drug Development

Final Five-Year Analysis of Phase 3 Data With ADSTILADRIN® (nadofaragene firadenovec-vncg) Shows Durable Bladder Preservation and Consistent Long-Term Safety in BCG-unresponsive NMIBC

Ferring Pharmaceuticals today announced the final 60-month follow-up data from the Phase 3 study of ADSTILADRIN® (nadofaragene firadenovec-vncg) were presented at the American Urological Association (AUA) 2024 Annual Meeting.

May 6, 2024
·
11 min read
Biotech Bay

Outset Medical’s TabloCart with Prefiltration Receives FDA 510(k) Clearance

Outset Medical, Inc. (Nasdaq: OM) (“Outset”) announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance of TabloCartTM with prefiltration, an innovative optional accessory for the Tablo® Hemodialysis System.

May 6, 2024
·
3 min read
Biotech Beach

Results from Pivotal Clinical Study Demonstrate Potential of Nucleix’s Bladder EpiCheck® to Improve Disease Recurrence Detection in Non-Muscle Invasive Bladder Cancer (NMIBC) Surveillance

Nucleix announced that the results from the company’s North American pivotal clinical study evaluating the performance of Bladder EpiCheck® as a non-invasive and objective novel methylation-based PCR urine test for the surveillance of non-muscle invasive bladder cancer (NMIBC) recurrence were presented in a podium presentation at the American Urological Association (AUA) Annual Meeting 2024 in San Antonio, Texas.

May 6, 2024
·
4 min read
Biotech Bay

Ansa Biotechnologies Expands Successful Early Access Program for Complex DNA Synthesis

Ansa Biotechnologies, Inc. today announced that it is expanding its early access program for its complex DNA synthesis services.

May 6, 2024
·
3 min read
Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect in Pancreatic Murine Tumor Models at ESTRO 2024 Congress in Glasgow

Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today the presentation of new preclinical data at the 2024 congress of the European Society for Radiotherapy and Oncology (ESTRO).

May 6, 2024
·
5 min read